DPX-Survivac Elicits Anti-Cancer Immune Activity in Recurrent OC, Data Show

DPX-Survivac Elicits Anti-Cancer Immune Activity in Recurrent OC, Data Show
DPX-Survivac combined with intermittent low-dose cyclophosphamide can generate significant anti-tumor immune responses that correlate with tumor regression in women with recurrent advanced ovarian cancer, latest results from the DECIDE1 Phase 2 trial show. Interim data announced by DPX-Survivac's developer, IMV, revealed that all 15 patients with smaller tumors (less than 5 cm at the study's start) experienced some level of clinical benefit from the combo treatment. This confirms prior Phase 1 findings demonstrating that smaller tumors had better responses to the combined treatment. Among these patients, four had their tumors regress enough to be considered a partial response, and remained without signs of disease progression over a significant period of time, researchers said. DECIDE1's most recent results are being presented at the
Subscribe or to access all post and page content.